Kirisits, A. and Wild, C. (2012): Efficacy of Hyperthermia Treatment in combination with radio- or chemotherapy in Breast-, Bladder-, Cervix Carcinoma and Soft Tissue Sarcoma patients. Update 2012. Decision Support Document 36 / Update 2012.

Wild, C. (2012): Avastin for Age-related Macular-Degeneration. Evidence synthesis after CATT, IVAN, MANTA. Rapid Assessment 005.

Joppi, R and Nachtnebel, A. (2012): Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma. DSD: Horizon Scanning in Oncology 34.

Fischer, S. and Zechmeister-Koss, I (2012): Day Surgery. HTA- Projektbericht 64.

Warmuth, M. and Stumpner, T. (2012): Therapeutic hypothermia (TH). Decision Support Document 63.

Zechmeister-Koss, I. and Reichel, M. (2012): Health status and access to health care of homeless people: A literature review. HTA-Projektbericht 63.

Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition). HTA-Projektbericht 41a.

Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2. updated edition). HTA-Projektbericht 41b.

Patera, N. and Piso, B. (2012): Occupational Therapy Part IV for Dementia and Part V for Depression. HTA- Projektbericht 60.

Dellinger, J. and Wild, C. (2012): Universal HIV-Testing. International Recommendations and actual risk of HIV-Infections for Healthcare-Workers. Decision Support Document 61.

Poggiani, C. and Nachtnebel, A. (2012): Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma. DSD: Horizon Scanning in Oncology 33.

Zechmeister-Koss, I. (2012): Standards on how to parameterise models via published literature: Input of the LBI-HTA for IFEDH work package 4. HTA- Projektbericht 58.

Warmuth, M. and Schumacher, I. (2012): Extracorporeal shock wave therapy (ESWT) in non-union or delayed union of fractures. Decision Support Document 62.

Jeitler, K. and Semlitsch , T. (2012): Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. DSD: Horizon Scanning in Oncology 32.

Nachtnebel, A. (2012): Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer. DSD: Horizon Scanning in Oncology 31.

Schumacher, I. and Piso, B. (2012): Occupational therapy. Part I: Status quo in Austria and part II: Occupational therapy for rheumatoid arthritis. HTA- Projektbericht 56.

Piso, B. and Tüchler, H. (2012): Outpatient cardiac rehabilitation. Part V: Study protocol "Multi-centre, prospective cohort study with two control groups (with/without phase III)". Decision Support Document 50.

Hintringer, K. (2012): Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma. DSD: Horizon Scanning in Oncology 29.

Zakosteletzki, L. and Nachtnebel, A. (2012): Horizon Scanning in Oncology - Impact evaluation and environmental analysis. HTA- Projektbericht 61.

Reinsperger, I. and Piso, B. (2012): Occupational Therapy Part III. Occupational therapy for patients after stroke. HTA- Projektbericht 59.

Nachtnebel, A. and Maran , P.R. and Alberti, C. and Garbaty , T. and Czeczot , J. (2012): Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion. DSD: Horizon Scanning in Oncology 28.

Joppi, R. and Nachtnebel, A. (2012): Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma . DSD: Horizon Scanning in Oncology 30.

Reichel, M. and Zechmeister-Koss, I. (2012): Renal denervation in patients with essential hypertension . Decision Support Document 45 / Update 2012.

Schiller-Frühwirth, I. and Wild, C. (2012): Intraoperative radiotherapy for primary breast cancer. Decision Support Document 23 / Update 2012.

Zechmeister-Koss, I. and Fischer, S. and Erdos, J. (2012): Re-orientation of the Austrian parent-child preventive care programme. Part VIII: Review of economic evaluations and budget impact analysis of outreach services and measures to reduce premature birth. HTA-Projektbericht 55.

Hintringer, K. (2012): Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL). DSD: Horizon Scanning in Oncology 26.

Hintringer, K. (2012): Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy. DSD: Horizon Scanning in Oncology 25.

Hintringer, K. (2012): Quality Appraisal of Written Consumer Health Information for Patients with Chronic Myeloid Leukaemia (CML) . HTA-Projektbericht 52.

Jeitler, K. and Semlitsch, T. (2012): Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer. DSD: Horizon Scanning in Oncology 27.

Winkler, R. and Erdos, J. and Wimmer, B. and Piso, B. (2012): Re-orientation of the Austrian parent-child preventive health care programme, Part VI: Health visiting services in the context of health care programmes for pregnant women, parents and children. HTA-Projektbericht 53.

Fischer, S. and Warmuth, M. (2012): Radiofrequency Ablation for the Treatment of Tumours of the Urogenital Tract (Renal Cell Carcinoma, Prostate Cancer and Uterine Leiomyoma). Decision Support Document 59.

Fischer, S. and Zechmeister-Koss, I. (2012): Radiofrequency Ablation for Treatment of Benign and Malignant Lesions of Endocrine Organs (Thyroid and Adrenal Gland). Decision Support Document 56.

Fischer, S. and Zechmeister-Koss, I. (2012): Radiofrequency Ablation for the Treatment of Head and Neck Cancer. Decision Support Document 55.

Warmuth, M. and Nachtnebel, A. (2012): Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes. Decision Support Document 53.

Fischer, S. and Zechmeister-Koss, I. (2012): Radiofrequency Ablation for the Treatment of Breast Cancer. Decision Support Document 57.

Mathis-Edenhofer, S. and Schramm, F. and Wild, C. (2012): Re-orientation of the Austrian parent-child preventive health care programme, Part VII: The potential of an electronic implementation. HTA- Projektbericht 54 .

Mathis-Edenhofer, S. and Kirisits, A. (2012): Sling suspension in male urinary incontinence. Decision Support Document 60.

Warmuth, M. and Nachtnebel, A. (2012): Radiofrequency ablation of bone tumours (osteoid-osteoma and osseous metastases). Decision Support Document 54.

Nachtnebel, A. and Reinsperger, I. (2012): Percutaneous repair of mitral regurgitation with the MitraClip® . Decision Support Document 41 / Update 2012.

Adlbrecht, C. and Warmuth, M. (2012): Radiofrequency ablation of primary tumours of the gastrointestinal tract (colorectal and pancreatic cancer). Decision Support Document 58.

Blagojevic, S. and Wild, C. (2012): Annual Report 2011. English Version.

Patera, N. and Wild, C. (2012): Generic indicators for process quality in oncological care: A compendium. HTA-Projektbericht 49b.

Wild, C. (2012): Cell therapy for urinary stress incontinence. Decision Support Document 06 / Update 2012.

Wild, C. and Blagojevic, S. (2012): Annual Report 2011. German Version.

Joppi, R. and Wild, C. (2012): Vemurafenib for patients with BRAF V600E mutation positive advanced/metastatic melanoma. DSD: Horizon Scanning in Oncology 23.

Nachtnebel, A. (2012): Erlotinib (Tarceva®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. DSD: Horizon Scanning in Oncology 22.

Ujeyl, M. (2012): Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin. DSD: Horizon Scanning in Oncology 24.

Schumacher, I. and Piso, B. (2012): Reorientation of the Austrian parent-child preventive care programme. Part V: Measures to reduce preterm birth. HTA-Projektbericht 50.

Poggiani, C. and Hintringer, K. (2012): Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC) . DSD: Horizon Scanning in Oncology 21.